Arcus Biosciences closes stock offering, raises $269.7 million net

Arcus Biosciences, Inc. entered into an underwriting agreement on October 21, 2026, with Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC as representatives of the underwriters, relating to the public offering, issuance and sale of 14,285,715 shares of common stock at a public offering price of $17.50 per share.¹

The company also granted the underwriters an option, exercisable for 30 days from the date of the agreement, to purchase up to an additional 2,142,857 shares at the public offering price, less underwriting discounts and commissions.¹ Separately, the underwriters agreed to purchase the shares of common stock from the company at a price of $16.45 per share.¹

The offering closed on October 23, 2026. The company completed the sale and issuance of an aggregate of 16,428,572 shares of common stock, including the exercise in full of the underwriters' option.¹ Net proceeds to the company totaled approximately $269.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.¹

The offering was made under an effective registration statement on Form S-3, Registration Statement No. 333-293750, along with an accompanying prospectus and preliminary and final prospectus supplements filed with the Securities and Exchange Commission.¹

A legal opinion from Latham & Watkins LLP regarding the legality of the issuance and sale of the securities was filed as an exhibit to the report.¹ The underwriting agreement itself was filed as Exhibit 1.1 to the filing.